| Medical and Health Sciences | Lifetime | 39 | KH 1 | 100.00 |
| Public, Environmental and Occupational Health | Lifetime | 3 | KH 1 | 100.00 |
| Epidemiology | Lifetime | 152 | KH 1 | 99.80 |
| Medicinal and Pharmaceutical Chemistry | Lifetime | 10 | KH 1 | 99.42 |
| Pharmacology | Lifetime | 47 | KH 1 | 99.56 |
| Parasitology | Lifetime | 120 | KH 1 | 98.65 |
| Pediatrics, Perinatology and Child Health | Lifetime | 555 | KH 2 | 98.33 |
| Computational Theory and Mathematics | Lifetime | 447 | KH 1 | 97.93 |
| Economic, Social and Gender History | Lifetime | 55 | KH 1 | 97.43 |
| Genetics | Lifetime | 894 | KH 1 | 97.80 |
| Infectious Diseases | Lifetime | 582 | KH 1 | 97.63 |
| History of Philosophy | Lifetime | 516 | KH 1 | 94.96 |
| Medical Genetics | Lifetime | 563 | KH 1 | 94.25 |
| Emergency Medicine | Lifetime | 728 | KH 1 | 92.22 |
| Endocrinology | Lifetime | 519 | KH 1 | 86.98 |
| Instrumentation and Measurement Physics | Lifetime | 571 | KH 1 | 60.81 |
| Public, Environmental and Occupational Health | 2021-2025 | 44 | KH 1 | 99.63 |
| Infectious Diseases | 2021-2025 | 466 | KH 1 | 90.23 |
| Mosquito-borne diseases and control | Lifetime | 1 | KH 1 | 99.99 |
| Computational Drug Discovery Methods | Lifetime | 1 | KH 1 | 99.96 |
| Malaria Research and Control | Lifetime | 1 | KH 1 | 100.00 |
| Drug-Induced Hepatotoxicity and Protection | Lifetime | 1 | KH 1 | 99.97 |
| Hemoglobinopathies and Related Disorders | Lifetime | 21 | KH 1 | 99.55 |
| Burkholderia infections and melioidosis | Lifetime | 2 | KH 1 | 99.84 |
| Parasites and Host Interactions | Lifetime | 19 | KH 1 | 99.71 |
| Drug Transport and Resistance Mechanisms | Lifetime | 47 | KH 1 | 99.66 |
| Pharmacological Effects and Toxicity Studies | Lifetime | 85 | KH 1 | 99.35 |
| Infectious Encephalopathies and Encephalitis | Lifetime | 18 | KH 1 | 99.01 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 117 | KH 1 | 99.29 |
| Complement system in diseases | Lifetime | 61 | KH 1 | 98.94 |
| Pharmacological Effects of Natural Compounds | Lifetime | 141 | KH 1 | 98.72 |
| Venomous Animal Envenomation and Studies | Lifetime | 44 | KH 1 | 98.47 |
| Pharmacogenetics and Drug Metabolism | Lifetime | 139 | KH 1 | 98.86 |
| Trypanosoma species research and implications | Lifetime | 119 | KH 1 | 98.83 |
| Travel-related health issues | Lifetime | 30 | KH 1 | 98.32 |
| Vector-borne infectious diseases | Lifetime | 169 | KH 1 | 98.58 |
| Analytical Methods in Pharmaceuticals | Lifetime | 171 | KH 1 | 97.80 |
| Research on Leishmaniasis Studies | Lifetime | 164 | KH 1 | 98.56 |
| Drug-Induced Ocular Toxicity | Lifetime | 26 | KH 1 | 97.31 |
| Epilepsy research and treatment | Lifetime | 438 | KH 1 | 98.01 |
| Neonatal Health and Biochemistry | Lifetime | 311 | KH 1 | 97.51 |
| HIV/AIDS drug development and treatment | Lifetime | 535 | KH 1 | 98.20 |
| Antibiotic Resistance in Bacteria | Lifetime | 923 | KH 1 | 97.59 |
| Asian Studies and History | Lifetime | 120 | KH 1 | 97.28 |
| Craniofacial Disorders and Treatments | Lifetime | 349 | KH 1 | 96.34 |
| Intramuscular injections and effects | Lifetime | 50 | KH 1 | 94.76 |
| Pharmaceutical Quality and Counterfeiting | Lifetime | 33 | KH 1 | 94.65 |
| Cleft Lip and Palate Research | Lifetime | 680 | KH 1 | 95.33 |
| Australian History and Society | Lifetime | 169 | KH 1 | 93.98 |
| Diphtheria, Corynebacterium, and Tetanus | Lifetime | 198 | KH 1 | 91.85 |
| Socioeconomic Development in Asia | Lifetime | 93 | KH 1 | 94.09 |
| Chemical Looping and Thermochemical Processes | Lifetime | 421 | KH 1 | 92.95 |
| Methemoglobinemia and Tumor Lysis Syndrome | Lifetime | 127 | KH 1 | 91.14 |
| Infections and bacterial resistance | Lifetime | 260 | KH 1 | 90.91 |
| Leptospirosis research and findings | Lifetime | 446 | KH 1 | 88.72 |
| Malaria Research and Control | 2021-2025 | 2 | KH 1 | 99.71 |
| Mosquito-borne diseases and control | 2021-2025 | 10 | KH 1 | 99.54 |
| Hemoglobinopathies and Related Disorders | 2021-2025 | 150 | KH 1 | 95.83 |
| Drug-Induced Hepatotoxicity and Protection | 2021-2025 | 99 | KH 1 | 93.76 |
| Methemoglobinemia and Tumor Lysis Syndrome | 2021-2025 | 7 | KH 1 | 87.43 |
| Parasites and Host Interactions | 2021-2025 | 192 | KH 1 | 92.77 |
| Computational Drug Discovery Methods | 2021-2025 | 993 | KH 1 | 90.77 |
| Neonatal Health and Biochemistry | 2021-2025 | 171 | KH 1 | 85.75 |
| Travel-related health issues | 2021-2025 | 62 | KH 1 | 86.91 |
| Parasitic Diseases Research and Treatment | 2021-2025 | 875 | KH 3 | 48.34 |
